MedTrace Logo

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT05005728 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2026-05-05

No results posted yet for this study

Summary

This Phase 2 study will investigate the safety and clinical activity of vudalimab (XmAb20717) alone or in combination with standard of care anticancer therapies in patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on prior therapy.

Conditions

Interventions

COMBINATION_PRODUCT

vudalimab + carboplatin + cabazitaxel

Vudalimab IV, carboplatin IV, cabazitaxel IV

COMBINATION_PRODUCT

vudalimab + olaparib

Vudalimab IV, olaparib oral

BIOLOGICAL

vudalimab monotherapy

Vudalimab IV

COMBINATION_PRODUCT

vudalimab + docetaxel

Vudalimab IV, docetaxel IV

COMBINATION_PRODUCT

vudalimab + cabazitaxel or docetaxel

Vudalimab IV, cabazitaxel or docetaxel IV

Sponsors & Collaborators

  • Xencor, Inc.

    lead INDUSTRY

Principal Investigators

  • Jolene Shorr · Xencor, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-22
Primary Completion
2025-06-10
Completion
2025-06-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05005728 on ClinicalTrials.gov